인도의 의약품 물류 시장 규모는 8.12%의 CAGR로 확대하며, 2025년 39억 3,000만 달러에서 2033년에는 73억 4,000만 달러로 성장할 것으로 예측됩니다. 인도의 물류 기업은 냉동 트럭, GPS 모니터가 장착된 컨테이너, 데이터 로거, 제약업체와의 제휴 등에 대한 투자를 통해 적응하고 있습니다. 인도의 의약품 물류 시장은 단순히 진화하고 있을 뿐만 아니라 컴플라이언스, 콜드체인 확장, 라스트 마일의 무결성을 중심으로 재조정되고 있습니다. 인도는 세계 최대 제네릭 의약품 공급국이자 백신의 중요한 공급국이기 때문에 의약품 물류에 대한 기대가 그 어느 때보다 높아지고 있습니다. 특히 바이오의약품과 특수 의약품에 대한 수요가 증가함에 따라 전통적인 창고에서 유통까지의 모델은 온도 모니터링, 디지털 추적, 실시간 가시성을 통해 다층적인 생태계로 진화하고 있습니다.
또한 의약품 공급망은 환자 중심으로 변화하고 있습니다. 전자 약국, 온도에 민감한 원료 의약품, 맞춤형 의료 증가로 인해 새로운 복잡한 계층이 도입되어 높은 서비스 수준, 신속한 이동, 엄격한 취급 프로토콜이 요구되고 있으며, PM Gati Shakti 프로그램 및 CDSCO(중앙 의약품 표준 관리 기관)의 가이드라인 개정과 같은 정부의 구상으로 다단계 운송의 연결성이 개선되고 보관 및 운송 조건의 조화가 이루어지고 있습니다. 또한 인도의 의약품 시장은 매우 성장하고 있습니다. 예를 들어 유엔인구기금(UNFPA)의 추산에 따르면 인도에서는 2050년까지 약 3억 4,700만 명이 60세 이상이 될 것으로 예측됩니다. 노년층은 질병에 걸리기 쉽기 때문에 의약품에 대한 수요가 더욱 증가하여 인도의 의약품 물류 시장을 촉진할 것으로 예측됩니다.
인도의 의약품 물류 시장에 대해 조사했으며, 시장의 개요와 유형별, 절차별, 컴포넌트별, 용도별, 운영별, 지역별 동향 및 시장에 참여하는 기업의 개요 등을 제공하고 있습니다.
Indian pharmaceutical logistics market is projected to witness a CAGR of 8.12% during the forecast period, FY2026-FY2033, growing from USD 3.93 billion in FY2025 to USD 7.34 billion in FY2033, driven by surging exports, rising domestic consumption, and increased regulatory scrutiny. India's logistics players are adapting through investments in reefer trucks, GPS-monitored containers, data loggers, and partnerships with pharmaceutical manufacturers. India's pharmaceutical logistics market is not just evolving, it is recalibrating around compliance, cold chain expansion, and last-mile integrity. With India being the world's largest provider of generic medicines and a critical supplier of vaccines, the stakes for pharma-grade logistics have never been higher. The traditional warehousing-to-distribution model has evolved into a multi-tiered ecosystem driven by temperature monitoring, digital tracking, and real-time visibility, particularly with the rising demand for biopharma and specialty drugs.
Moreover, the pharma supply chain is becoming more patient-centric. The growth of e-pharmacies, temperature-sensitive APIs, and personalized medicine has introduced a new complexity layer, demanding high service levels, rapid fulfillment, and strict handling protocols. Government initiatives such as the PM Gati Shakti programme and revised guidelines under CDSCO (Central Drugs Standard Control Organization) are improving multimodal connectivity and harmonizing storage and transit conditions. Additionally, the Indian pharmaceutical market is growing enormously. For instance, as per the estimates of the United Nations Population Fund (UNFPA), approximately 347 million individuals in India are expected to be sixty or older by 2050. This is further expected to boost the requirement for pharmaceuticals as the elderly are more susceptible to diseases, driving the India pharmaceutical logistics market.
Market Growth due to Surge in Cold Chain Demand Due to Biopharma and Specialty Drugs
Cold chain logistics is no longer a niche in India; it is becoming the standard for high-value pharmaceutical movement. Biologics, vaccines, insulin, and advanced therapies require a tightly controlled cold chain infrastructure, from production to the patient.
In September 2023, India's Ministry of Health & Family Welfare issued new draft norms requiring mandatory validation of cold storage facilities for vaccine and insulin supply chains, both for public and private sector logistics players. This has led to a significant private sector response. In January 2024, Snowman Logistics inaugurated a new pharma-grade cold storage facility in the Northeast in January 2024, adding around 5,000 pallets of 2-8°C storage, specifically catering to vaccine and biologics clients in western India.
The rising demand from clinical trials and the growing portfolio of India's biopharma exports, including mRNA and biosimilars, are also pushing 3PLs to upgrade infrastructure. Gati Kausar and ColdEx have both announced fleet expansion plans for pharma-grade reefer trucks with continuous temperature monitoring. Cold chain is no longer an optional add-on; it is a competitive mandate.
Multimodal Logistics Expansion and Policy Support Leading to an Increase in Market Reach
Logistics players are finally moving beyond just roads. India's multimodal push, especially under PM Gati Shakti, is reconfiguring pharma logistics routes for better time-cost efficiency. Rail and air freight are gaining traction for high-value, low-volume drugs that need speed and precision.
In February 2024, the Indian Railways launched Pharma Express, a dedicated temperature-controlled freight service between Hyderabad and Delhi, with pre-booked reefer containers and validated SOPs in partnership with logistics players such as TCI Express Limited and Allcargo Logistics Limited.
Meanwhile, air cargo terminals in Delhi, Mumbai, and Hyderabad have seen capacity upgrades, including pharma corridors with end-to-end cold chain monitoring, coordinated by the Air Cargo Forum India (ACFI) and AAI Cargo Logistics & Allied Services (AAICLAS).
The growing export of bulk drugs, APIs, and high-value generics, particularly to the U.S. and Europe, is making multimodal logistics not just viable but essential. Add to this, policy-level clarity around standardization, and logistics firms now have an environment conducive to infrastructure scaling.
Dominance of Biopharma Application in Logistics Spend
Among all pharmaceutical verticals, biopharma commands the highest logistics complexity and spend, making it the dominant segment in India's pharmaceutical logistics landscape. Biopharmaceuticals have stringent temperature requirements (2-8 degrees Celsius or even 20 degrees Celsius for some mAbs), short shelf lives, and often involve bulk movement to centralized cold chain hubs for global distribution. With India emerging as a preferred CDMO (Contract Development and Manufacturing Organization) partner for global biologics, logistics has taken center stage.
In July 2023, Biocon Biologics expanded its export footprint by shipping biosimilars from its Bengaluru site to 70 countries, supported by partnerships with Stellar Value Chain Solutions for packaging, conditioning, and validated route mapping.
Biopharma also includes temperature-sensitive clinical trial logistics - an area that has grown as India becomes a testbed for global Phase II/III studies. Logistics providers catering to this segment are adding passive containers, validated SOPs, and a GDP-trained workforce to maintain regulatory compliance. This sub-sector's precision demands are setting new industry benchmarks and commanding premium pricing in logistics contracts.
Impact of U.S. Tariffs on India Pharmaceutical Logistics Market
U.S. tariffs on pharmaceuticals on Indian goods and pharma products will disrupt India's pharmaceutical exports, and the pharma supply chain will largely impact "exports" & "cost to the supply chain." Specifically, the U.S. can impose higher tariffs on drugs or APIs manufactured in India. Increased pharmaceutical logistics providers may face the following issues: Reduced export, increased warehousing diversification in other markets such as Africa, Europe, and Latin America, exponentially high input costs: Raw materials are expensive or increase prices, e.g., tariffs on "Chinese intermediates used in Indian pharma." Increases warehousing and transportation costs, such as the cold chain, which is more expensive.
Key Players Landscape and Outlook
India's pharmaceutical logistics market is relatively fragmented, but clear leaders are emerging based on service specialization, cold chain depth, and multimodal adaptability. Snowman Logistics, Gati Kausar, and ColdEx lead the cold chain space with pharma-grade warehouses and reefer fleets. Stellar Value Chain and TCI Express are strong in multi-zone transport and compliance-driven packaging solutions. Many players are integrating real-time visibility platforms, investing in blockchain-based tracking, and training the workforce under WHO-GDP guidelines. Mahindra Logistics Limited and Reefer Express, though smaller, have carved out niches in intra-state biopharma supply. What differentiates players now is not just delivery timelines, but how well they can comply, monitor, and adapt in an increasingly regulated and digitized ecosystem.
In December 2023, the boards of Allcargo Logistics Limited and Allcargo Gati Limited approved a composite scheme of arrangement to restructure their businesses. Under the plan, the International Supply Chain (ISC) business-including both the India operations and international subsidiaries-demerged into a new entity, Allcargo ECU Limited. The remaining express and contract logistics businesses were consolidated under Allcargo Logistics. This restructuring aimed to simplify the corporate structure, enhance synergies, and provide direct shareholding to Allcargo and Allcargo Gati shareholders.
Companies mentioned above DO NOT hold any order as per market share and can be changed as per information available during research work.